AOD-9604 3.6mg
Fat-burning fragment of HGH — tissue repair & metabolic support
Full Details & Dosage GuideClinical Uses
- Tissue repair and injury recovery
- Post-surgical healing support
- Cartilage and ligament regeneration
- Chronic pain and inflammation reduction
- Fat metabolism and body recomposition
Key Benefits
- Stimulates natural fat-burning pathways without affecting blood sugar
- Accelerates healing of muscle and connective tissue
- Anti-inflammatory properties reduce recovery time
- No impact on IGF-1 or insulin sensitivity
- Well-tolerated with a strong long-term safety profile
How It Works
AOD-9604 is a stabilized fragment of the C-terminus of human growth hormone (hGH), specifically residues 177-191. It mimics the fat-metabolizing effects of hGH without stimulating IGF-1 production. It activates β3-adrenergic receptors in adipose tissue, directly triggering lipolysis (fat breakdown) while simultaneously inhibiting lipogenesis (fat creation).
Dosage Protocol
300–500 mcg subcutaneous injection daily, administered in the morning on an empty stomach. Best results when combined with a 15–20 minute fasting window post-injection. Cycle: 3 months on, 1 month off.
When to Expect Results
Weeks 2–4: improved recovery and reduced inflammation. Weeks 4–8: visible body composition changes. Weeks 8–12: significant fat reduction and tissue remodeling. Full metabolic benefits consolidate at 90 days.
AOD-9604 15mg
High-dose fat-burning fragment of HGH — advanced protocol
Full Details & Dosage GuideClinical Uses
- Tissue repair and injury recovery
- Post-surgical healing support
- Cartilage and ligament regeneration
- Chronic pain and inflammation reduction
- Fat metabolism and body recomposition
Key Benefits
- Stimulates natural fat-burning pathways without affecting blood sugar
- Accelerates healing of muscle and connective tissue
- Anti-inflammatory properties reduce recovery time
- No impact on IGF-1 or insulin sensitivity
- Well-tolerated with a strong long-term safety profile
How It Works
AOD-9604 is a stabilized fragment of the C-terminus of human growth hormone (hGH), specifically residues 177-191. It mimics the fat-metabolizing effects of hGH without stimulating IGF-1 production. It activates β3-adrenergic receptors in adipose tissue, directly triggering lipolysis (fat breakdown) while simultaneously inhibiting lipogenesis (fat creation).
Dosage Protocol
300–500 mcg subcutaneous injection daily, administered in the morning on an empty stomach. Best results when combined with a 15–20 minute fasting window post-injection. Cycle: 3 months on, 1 month off.
When to Expect Results
Weeks 2–4: improved recovery and reduced inflammation. Weeks 4–8: visible body composition changes. Weeks 8–12: significant fat reduction and tissue remodeling. Full metabolic benefits consolidate at 90 days.
BPC-157 6mg
Body Protection Compound — gut healing, tendon & tissue repair
Full Details & Dosage GuideClinical Uses
- Cardiovascular tissue repair
- Organ protection (liver, kidney, pancreas)
- Systemic wound healing and inflammation
- Athletic recovery and connective tissue repair
- Post-surgical healing
- Chronic disease tissue protection
Key Benefits
- Dual-pathway: BPC-157 drives angiogenesis; TB-500 drives cellular migration
- Reduces inflammation while promoting regeneration simultaneously
- Systemic reach — protects organs distant from injection site
- Significant cardioprotective effects in ischemia models
- Well-tolerated combination with decades of research
How It Works
BPC-157 stimulates VEGF-mediated angiogenesis and FAK-paxillin cellular migration, directly repairing damaged tissue microvasculature. TB-500 promotes actin polymerization through its Ac-SDKP sequence, enabling cell motility and tissue remodeling. In the cardiovascular system, BPC-157 preserves endothelial integrity post-ischemia while TB-500 supports cardiomyocyte survival and vascular remodeling.
Dosage Protocol
BPC-157: 250–500 mcg + TB-500: 500 mcg–2 mg subcutaneous injection, 1–2x daily. Co-administer at adjacent sites. Cardiovascular protocol: 4–8 weeks with cardiologist oversight.
When to Expect Results
Days 3–7: reduction in pain and inflammation. Weeks 2–3: improved tissue perfusion and healing. Weeks 4–6: measurable functional recovery. Weeks 6–8: significant organ-level regeneration and inflammatory marker normalization.
BPC-157 15mg
High-dose BPC-157 for advanced recovery protocols
Full Details & Dosage GuideClinical Uses
- Cardiovascular tissue repair
- Organ protection (liver, kidney, pancreas)
- Systemic wound healing and inflammation
- Athletic recovery and connective tissue repair
- Post-surgical healing
- Chronic disease tissue protection
Key Benefits
- Dual-pathway: BPC-157 drives angiogenesis; TB-500 drives cellular migration
- Reduces inflammation while promoting regeneration simultaneously
- Systemic reach — protects organs distant from injection site
- Significant cardioprotective effects in ischemia models
- Well-tolerated combination with decades of research
How It Works
BPC-157 stimulates VEGF-mediated angiogenesis and FAK-paxillin cellular migration, directly repairing damaged tissue microvasculature. TB-500 promotes actin polymerization through its Ac-SDKP sequence, enabling cell motility and tissue remodeling. In the cardiovascular system, BPC-157 preserves endothelial integrity post-ischemia while TB-500 supports cardiomyocyte survival and vascular remodeling.
Dosage Protocol
BPC-157: 250–500 mcg + TB-500: 500 mcg–2 mg subcutaneous injection, 1–2x daily. Co-administer at adjacent sites. Cardiovascular protocol: 4–8 weeks with cardiologist oversight.
When to Expect Results
Days 3–7: reduction in pain and inflammation. Weeks 2–3: improved tissue perfusion and healing. Weeks 4–6: measurable functional recovery. Weeks 6–8: significant organ-level regeneration and inflammatory marker normalization.
CJC 3mg (No DAC)
Growth hormone releasing peptide — pulse GH secretion
Full Details & Dosage GuideClinical Uses
- Growth hormone secretagogue therapy
- Anti-aging and body recomposition
- Sleep quality optimization
- Muscle mass and recovery support
- Metabolic enhancement
Key Benefits
- Stimulates pulsatile GH release matching natural circadian rhythm
- Shorter half-life preserves natural GH pulsatility
- Improves deep sleep architecture (stages 3 and 4)
- Lean muscle gain with concomitant fat loss
- No receptor desensitization at standard doses
How It Works
CJC-1295 No DAC (Mod GRF 1-29) is a 29-amino-acid analog of GHRH. Without the Drug Affinity Complex (DAC), it has a half-life of approximately 30 minutes, producing a sharp, physiological GH pulse that mimics the natural GH secretory pattern. It binds the pituitary GHRH receptor, triggering GH synthesis and release.
Dosage Protocol
100–200 mcg subcutaneous injection 2–3 times daily (morning, post-workout, and before bed). Best results when stacked with Ipamorelin 200–300 mcg. Inject fasted or 2 hours post-meal.
When to Expect Results
Week 1–2: improved sleep depth and recovery. Weeks 3–6: increased strength, improved body composition. Weeks 6–12: significant lean mass accrual and fat reduction.
CJC 3mg / Ipamorelin 6mg
Synergistic GH stack — optimised recovery & body composition
Full Details & Dosage GuideClinical Uses
- Optimized growth hormone secretion
- Anti-aging protocols
- Body recomposition
- Injury recovery
- Sleep architecture improvement
Key Benefits
- Synergistic dual-pathway GH stimulation
- Ipamorelin blocks somatostatin — removing the body's GH brake
- No cortisol or prolactin spike
- Improves IGF-1 levels within 4–6 weeks
- Minimal side effects
How It Works
CJC-1295 No DAC stimulates the GHRH receptor for GH synthesis while Ipamorelin blocks somatostatin. Together they produce a GH pulse 2–5x larger than either alone, free of cortisol or prolactin elevation.
Dosage Protocol
CJC: 100–200 mcg + Ipamorelin: 200–300 mcg subcutaneous 2–3x daily. Morning fasted, post-workout, and 30 min before sleep. 5 days on, 2 off. 3–6 month run.
When to Expect Results
Week 1–2: deeper sleep and faster recovery. Weeks 3–6: body composition changes. Weeks 8–12: measurable IGF-1 increase and lean mass gain.
CJC 6mg / Ipamorelin 6mg
High-dose CJC/Ipamorelin combination for maximum GH release
Full Details & Dosage GuideClinical Uses
- Advanced growth hormone optimization
- Performance and body recomposition
- Longevity protocols
- Post-injury tissue regeneration
- Metabolic enhancement
Key Benefits
- Higher-dose CJC for stronger GH stimulus
- Extends pituitary GH-secreting capacity
- Improved skin elasticity and collagen synthesis
- Superior fat mobilization
- Enhanced recovery
How It Works
Same dual GHRH/ghrelin mechanism as standard CJC/Ipamorelin, with higher CJC-1295 dosing providing more sustained pituitary stimulation. The 6mg vial supports extended protocols.
Dosage Protocol
CJC: 150–300 mcg + Ipamorelin: 200–300 mcg subcutaneous 2–3x daily. Best fasted. 5 days on, 2 days off. Labs at 6-week intervals.
When to Expect Results
Weeks 1–2: sleep improvement and reduced soreness. Weeks 4–6: body composition shifts. Weeks 8–12: visible lean mass increase and visceral fat reduction.
Ipamorelin 6mg
Clean GH secretagogue — minimal side effects, strong pulse
Full Details & Dosage GuideClinical Uses
- Growth hormone secretagogue monotherapy
- Sleep and recovery optimization
- Gentle anti-aging protocol
- Body recomposition support
Key Benefits
- Most selective GH secretagogue — no cortisol, no prolactin, no appetite stimulation
- Ideal for GH optimization without polypharmacy
- Improves sleep quality and morning recovery significantly
- Suitable for long-term use without receptor downregulation
- Well-tolerated by both men and women
How It Works
Ipamorelin is a third-generation GHRP and selective ghrelin receptor agonist. Unlike GHRP-2 or GHRP-6, it produces GH release without stimulating cortisol, prolactin, or appetite — making it the cleanest available GH secretagogue. Acts on the ghrelin receptor in the pituitary, triggering selective somatotroph activation.
Dosage Protocol
200–300 mcg subcutaneous injection 2–3x daily: morning fasted, post-workout (optional), and 30–60 minutes before sleep. Monotherapy cycle: 3–6 months. Stack with CJC-1295 for synergistic response.
When to Expect Results
Week 1: improved sleep depth and morning alertness. Weeks 2–4: recovery acceleration. Weeks 4–8: body composition improvements. Weeks 8–16: IGF-1 increase measurable on labs.
Sermorelin 3mg
GHRH analogue — stimulates natural growth hormone release
Full Details & Dosage GuideClinical Uses
- Age-related GH deficiency
- Pituitary function assessment and restoration
- Anti-aging hormone optimization
- Lean body mass improvement
- Recovery from chronic stress or overtraining
Key Benefits
- FDA-approved GHRH analog — one of the most studied GH secretagogues
- Restores natural pituitary GH secretion rather than bypassing it
- Improves bone mineral density over time
- Enhances skin texture and collagen density
- Associated with improved mood and cognitive clarity
How It Works
Sermorelin is a 29-amino-acid analog of naturally occurring GHRH (the first 29 residues) — the closest pharmaceutical approximation to endogenous GHRH. It binds pituitary GHRH receptors, stimulating GH synthesis and secretion in a physiological, pulsatile manner. Unlike exogenous HGH, it preserves the hypothalamic-pituitary feedback loop, preventing IGF-1 excess.
Dosage Protocol
200–300 mcg subcutaneous injection before bedtime daily. Administer on an empty stomach for maximum pituitary response. Can be stacked with Ipamorelin. Minimum 3-month protocol; 6 months for full anti-aging benefit.
When to Expect Results
Weeks 1–3: improved sleep quality and recovery. Weeks 4–8: body composition changes begin, energy improves. Weeks 8–16: visible muscle tone improvement, skin changes. Months 4–6: IGF-1 normalization and maximum anti-aging effect.
Tesamorelin 30mg
FDA-studied GHRH analogue — visceral fat reduction & muscle preservation
Full Details & Dosage GuideClinical Uses
- Visceral adiposity reduction
- FDA-approved treatment for HIV-associated lipodystrophy
- GH deficiency in adults
- Metabolic syndrome
- Cardiovascular risk profile improvement
Key Benefits
- FDA-approved for visceral fat reduction
- Significantly reduces trunk fat without affecting subcutaneous fat
- Improves triglycerides and lipid profiles
- Increases IGF-1 and lean body mass
- Multiple Phase III clinical trials
How It Works
Tesamorelin is a stabilized GHRH analog with a trans-3-hexenoic acid group extending half-life. Binds pituitary GHRH receptors stimulating pulsatile GH release. Visceral adipocytes have higher GH receptor density than subcutaneous fat cells — making them preferentially lipolyzed by GH stimulation.
Dosage Protocol
1–2 mg subcutaneous injection once daily in the abdomen. Morning on empty stomach. Protocols typically 6–12 months. DEXA and IGF-1 at 3-month intervals.
When to Expect Results
Weeks 4–8: measurable waist circumference reduction. Weeks 8–16: significant trunk fat loss on DEXA. Months 3–6: improved lipid panel, IGF-1 normalization, visible abdominal definition.
IGF-1 LR3 300mcg
Insulin-like Growth Factor — muscle growth & cellular repair
Full Details & Dosage GuideMGF 2.4mg
Mechano Growth Factor — local muscle repair & satellite cell activation
Full Details & Dosage GuideClinical Uses
- Localized muscle fiber repair and hypertrophy
- Post-injury muscle regeneration
- Satellite cell activation
- Performance enhancement for athletes
- Recovery from muscle tears or strains
Key Benefits
- Specifically activates satellite (stem) cells in muscle tissue
- Promotes local muscle repair faster than systemic IGF-1
- Increases muscle fiber cross-sectional area
- Works synergistically with IGF-1 LR3
- Reduces recovery time between intense sessions
How It Works
Mechano Growth Factor (MGF) is a splice variant of the IGF-1 gene expressed in response to mechanical loading and muscle damage. Its unique E-peptide domain activates muscle satellite cells (adult muscle stem cells) to proliferate and differentiate into new muscle fibers — distinct from the systemic anabolic effects of standard IGF-1.
Dosage Protocol
100–200 mcg intramuscular injection into the target muscle immediately post-workout. Training days only. Best stacked: MGF immediately post-workout, IGF-1 LR3 several hours later. Cycle: 4 weeks on, 4 weeks off.
When to Expect Results
Days 2–5: significant reduction in DOMS. Weeks 2–3: improved muscle fullness. Week 4: measurable hypertrophy in targeted muscle group.
DSIP 2mg
Delta Sleep-Inducing Peptide — deep sleep, GH pulse & stress regulation
Full Details & Dosage GuideClinical Uses
- Chronic insomnia and sleep architecture repair
- Stress-related sleep disruption
- Cortisol normalization
- Recovery from overtraining syndrome
- Pain modulation
Key Benefits
- Directly improves slow-wave (deep) sleep and REM sleep duration
- Reduces nighttime cortisol and ACTH levels
- Non-habit-forming — does not cause rebound insomnia
- Reduces pain sensitivity without opiate-like dependence
- Supports adrenal recovery in HPA axis dysregulation
How It Works
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide that modulates the HPA axis, reducing CRH and ACTH output while normalizing nocturnal cortisol rhythms. It acts on limbic system receptors to facilitate the transition into deep sleep, increase delta wave activity, and reduce nocturnal stress hormone bursts.
Dosage Protocol
100–300 mcg subcutaneous injection 30–60 minutes before bedtime. Start at lower dose and titrate. Can stack with CJC/Ipamorelin at bedtime. 4–8 week cycles.
When to Expect Results
Night 1–3: improved sleep onset and deeper sleep. Week 1–2: sustained sleep quality improvement. Week 3–6: cortisol normalization. Full HPA recovery at 6–8 weeks.
CJC / Ipamorelin / DSIP
Triple GH stack with sleep peptide — recovery, body composition & rest
Full Details & Dosage GuideClinical Uses
- Comprehensive sleep, recovery, and GH optimization
- Anti-aging night protocol
- Post-competition athlete recovery
- Adrenal fatigue and overtraining syndrome
Key Benefits
- Triple-mechanism nighttime stack: GH release + somatostatin blockade + deep sleep induction
- Maximizes anabolic GH window during sleep
- Reduces cortisol while boosting GH
- Improves body composition, recovery, and cognitive performance simultaneously
How It Works
CJC-1295 No DAC stimulates GHRH receptor for GH synthesis; Ipamorelin blocks somatostatin; DSIP promotes delta wave sleep and HPA axis normalization. Together: maximum GH pulse during deep sleep with no cortisol interference — the optimal neuroendocrine environment for nighttime regeneration.
Dosage Protocol
CJC: 100–200 mcg + Ipamorelin: 200–300 mcg + DSIP: 100–200 mcg. All subcutaneous 30–45 min before sleep. 5 days on, 2 days off. 3–6 month protocols.
When to Expect Results
Night 1–3: significantly deeper sleep. Weeks 1–2: improved morning recovery. Weeks 4–8: body composition shifts and IGF-1 rise. Weeks 8–16: full anti-aging and regenerative benefit.
All peptides require UAE licensed physician review and mandatory blood work before dispensing. All protocols are subject to physician approval. Results vary by individual. These statements are for informational purposes only and do not constitute medical advice.